Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study
- 27 May 2004
- journal article
- clinical trial
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 130 (7) , 400-404
Abstract
Combining anthracyclines and taxanes are to date the most active cytotoxic treatment option in the neoadjuvant and palliative therapy of breast cancer patients. Adding trastuzumab to these cytotoxic agents can improve outcome for women with human epidermal growth factor receptor 2 (HER2)-overexpressing advanced breast cancer. We conducted a pilot study of preoperative epidoxorubicin and docetaxel plus trastuzumab in outpatient patients suffering from breast cancer.Keywords
This publication has 16 references indexed in Scilit:
- Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancerCancer Chemotherapy and Pharmacology, 2002
- Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factorAnti-Cancer Drugs, 2002
- Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene AmplificationJournal of Clinical Oncology, 2001
- The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?European Journal of Cancer, 2000
- Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk FactorsJournal of Clinical Oncology, 1999
- Phase II of doxorubicin/taxol in metastatic breast cancerBreast Cancer Research and Treatment, 1999
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1998
- Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.Journal of Clinical Oncology, 1997
- A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTCBritish Journal of Cancer, 1996
- Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6European Journal of Cancer, 1994